Literature DB >> 6848879

Acquired ventricular septal defect.

D J Keenan, J L Monro, J K Ross, J M Manners, N Conway, A M Johnson.   

Abstract

The past 9 years' experience with ventricular septal rupture complicating myocardial infarction has been reviewed. Thirty-six patients were treated surgically, with 10 early deaths (28%) and one late death, for an 8 year actuarial survival rate of 63%. The mortality was highest for those defects which followed inferior infarction, 38% compared with 13% following anterior infarction. The infarction-operation interval also greatly influenced mortality; under 2 weeks, 43%; over 2 weeks, 18%. Concomitant coronary artery bypass grafts (13 patients) or left ventricular aneurysmectomy (14 patients) did not carry an increased mortality. Of 17 patients who presented with cardiogenic shock, eight died (47%). The intra-aortic balloon pump (IABP) was used in 16 patients (44%) and helped greatly in the management of the critically ill. With an estimated 17 acquired septal defects occurring each year in persons under 65 years of age in Wessex, awareness of this complication and of the favorable outcome of operation is essential among those who treat the aftereffects of myocardial infarction.

Entities:  

Mesh:

Year:  1983        PMID: 6848879

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Diagnosis of ventricular septal rupture after myocardial infarction: value of colour flow mapping.

Authors:  J Smyllie; K Dawkins; N Conway; G R Sutherland
Journal:  Br Heart J       Date:  1989-10

2.  Ventricular septal rupture with "normal" coronary arteries.

Authors:  J V Richardson; G S Niess
Journal:  Tex Heart Inst J       Date:  1985-03

3.  Successful management of mechanical complications following acute myocardial infarction--a case report.

Authors:  D G Park; G B Nam; M M Lee; Y B Park; Y S Choi; J D Seo; Y W Lee; H Chae; Y D Kim
Journal:  Korean J Intern Med       Date:  1991-07       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.